MDA-MB-231-Luc

MDA-MB-231-Luciferase is a bioluminescent derivative of the MDA-MB-231 human breast cancer cell line, genetically engineered to express firefly-Luc. This modification enables sensitive, non-invasive detection of tumor burden and metastatic dissemination in live animal models through bioluminescence imaging (BLI). Upon administration of the-Luc substrate D-luciferin, these cells emit light that can be quantified using imaging systems, allowing for dynamic monitoring of tumor growth, metastatic colonization, and therapeutic response over time without the need for repeated invasive procedures.

As a triple-negative breast cancer (TNBC) model, the parental MDA-MB-231 line is ER-, PR-, and HER2-negative, and is characterized by a mesenchymal, invasive phenotype. The-Luc-expressing variant retains these aggressive features and is frequently used in xenograft and metastasis models, particularly to study organotropism such as bone, lung, or brain metastasis. Its high tumorigenic potential in immunocompromised mice combined with-Luc expression makes MDA-MB-231-Luciferase a powerful tool for quantifying tumor dynamics in real time and evaluating anti-cancer drug efficacy, especially in preclinical therapeutic studies targeting metastasis or microenvironmental interactions.

While the-Luc label itself does not alter the inherent biological behavior of the MDA-MB-231 cells, batch-specific validation is recommended to confirm that-Luc integration does not influence proliferation, invasion, or drug response in a given experimental context. This line is especially useful for applications requiring longitudinal tracking, including orthotopic mammary fat pad implantation, tail vein injection for experimental metastasis, or intracardiac injection to model systemic dissemination.